Paxlovid effective in reducing COVID-19 hospitalization among vaccinated adults 50 and over

Glass laboratory flasks on light table

The antiviral drug nirmatrelvir plus ritonavir (Paxlovid) was granted Emergency Use Authorization for treating COVID-19 in December 2021. In clinical trials, the antiviral was associated with an 88% reduction in hospitalization or death among high-risk, unvaccinated individuals with COVID-19.

Adults who neglect COVID-19 health recommendations may also neglect basic road safety, study finds

Previous article

How CitizenShipper Uses Community to Catapult Their Company Forward

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations